Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

NCT02824003 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: ISIS-GCGRRx
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.